Background: It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact. Methods: We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014. Standardized incidence ratios (SIRs) quantified second cancer risk. We assessed impact of second cancer development on risk of all-cause mortality using Cox regression. Results: Among 151 949 one-or-more-year survivors of first primary LN, second primary CM risk was statistically significantly elevated after chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR = 1.96, 95% confidence interval [CI] = 1.74 to 2.21), follicular lymphoma (SIR = 1.32, 95% CI = 1.09 to 1.58), and plasma cell neoplasms (SIR = 1.33, 95% CI = 1.07 to 1.63). Risks for these same subtypes were statistically significantly elevated among 148 336 survivors of first primary CM (SIR = 1.44, 95% CI = 1.25 to 1.66; SIR = 1.47, 95% CI = 1.21 to 1.77; SIR = 1.25, 95% CI = 1.06 to 1.47; respectively). Risk for CM was statistically significantly elevated after diffuse large B-cell lymphoma (SIR = 1.22, 95% CI = 1.02 to 1.45) and Hodgkin lymphoma (SIR = 1.75, 95% CI = 1.33 to 2.26), but the reciprocal relationship was not observed. There were no statistically significant associations between marginal zone lymphoma and CM. Among survivors of most LN subtypes, CM statistically significantly increased risk of death (hazard ratio [HR] range = 1.52, 95% CI = 1.25 to 1.85, to 2.46, 95% CI = 1.45 to 4.16). Among survivors of CM, LN statistically significantly increased risk of death (HR range = 1.75, 95% CI = 1.15 to 2.65, to 6.28, 95% CI = 5.00 to 7.88), with the highest risks observed for the most aggressive LN subtypes. Conclusions: Heterogeneous associations between CM and specific LN subtypes provide novel insights into the etiology of these malignancies, with the mutual association between CM and certain LN suggesting shared etiology. Development of second primary CM or LN substantially reduces overall survival.
Background: It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact. Methods: We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014. Standardized incidence ratios (SIRs) quantified second cancer risk. We assessed impact of second cancer development on risk of all-cause mortality using Cox regression. Results: Among 151 949 one-or-more-year survivors of first primary LN, second primary CM risk was statistically significantly elevated after chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR = 1.96, 95% confidence interval [CI] = 1.74 to 2.21), follicular lymphoma (SIR = 1.32, 95% CI = 1.09 to 1.58), and plasma cell neoplasms (SIR = 1.33, 95% CI = 1.07 to 1.63). Risks for these same subtypes were statistically significantly elevated among 148 336 survivors of first primary CM (SIR = 1.44, 95% CI = 1.25 to 1.66; SIR = 1.47, 95% CI = 1.21 to 1.77; SIR = 1.25, 95% CI = 1.06 to 1.47; respectively). Risk for CM was statistically significantly elevated after diffuse large B-cell lymphoma (SIR = 1.22, 95% CI = 1.02 to 1.45) and Hodgkin lymphoma (SIR = 1.75, 95% CI = 1.33 to 2.26), but the reciprocal relationship was not observed. There were no statistically significant associations between marginal zone lymphoma and CM. Among survivors of most LN subtypes, CM statistically significantly increased risk of death (hazard ratio [HR] range = 1.52, 95% CI = 1.25 to 1.85, to 2.46, 95% CI = 1.45 to 4.16). Among survivors of CM, LN statistically significantly increased risk of death (HR range = 1.75, 95% CI = 1.15 to 2.65, to 6.28, 95% CI = 5.00 to 7.88), with the highest risks observed for the most aggressive LN subtypes. Conclusions: Heterogeneous associations between CM and specific LN subtypes provide novel insights into the etiology of these malignancies, with the mutual association between CM and certain LN suggesting shared etiology. Development of second primary CM or LN substantially reduces overall survival.
Authors: Appathurai Balamurugan; Judy R Rees; Carol Kosary; Sun Hee Rim; Jun Li; Sherri L Stewart Journal: J Am Acad Dermatol Date: 2011-11 Impact factor: 11.527
Authors: Rebecca J Critchley-Thorne; Diana L Simons; Ning Yan; Andrea K Miyahira; Frederick M Dirbas; Denise L Johnson; Susan M Swetter; Robert W Carlson; George A Fisher; Albert Koong; Susan Holmes; Peter P Lee Journal: Proc Natl Acad Sci U S A Date: 2009-05-18 Impact factor: 11.205
Authors: Yutaka Yasui; Yan Liu; Joseph P Neglia; Debra L Friedman; Smita Bhatia; Anna T Meadows; Lisa R Diller; Ann C Mertens; John Whitton; Leslie L Robison Journal: Am J Epidemiol Date: 2003-12-01 Impact factor: 5.363
Authors: C A Clarke; L M Morton; C Lynch; R M Pfeiffer; E C Hall; T M Gibson; D D Weisenburger; O Martínez-Maza; S K Hussain; J Yang; E T Chang; E A Engels Journal: Br J Cancer Date: 2013-06-11 Impact factor: 9.075
Authors: Hilary A Robbins; Christina A Clarke; Sarah T Arron; Zaria Tatalovich; Amy R Kahn; Brenda Y Hernandez; Lisa Paddock; Elizabeth L Yanik; Charles F Lynch; Bertram L Kasiske; Jon Snyder; Eric A Engels Journal: J Invest Dermatol Date: 2015-08-13 Impact factor: 7.590
Authors: Megan M Herr; Rochelle E Curtis; Margaret A Tucker; Heather R Tecca; Eric A Engels; Elizabeth K Cahoon; Minoo Battiwalla; David Buchbinder; Mary E Flowers; Ruta Brazauskas; Bronwen E Shaw; Lindsay M Morton Journal: J Am Acad Dermatol Date: 2019-10-22 Impact factor: 11.527
Authors: Ulrike Leiter; Carmen Loquai; Lydia Reinhardt; David Rafei-Shamsabadi; Ralf Gutzmer; Katharina Kaehler; Lucie Heinzerling; Jessica C Hassel; Valerie Glutsch; Judith Sirokay; Nora Schlecht; Albert Rübben; Thilo Gambichler; Kerstin Schatton; Claudia Pfoehler; Cindy Franklin; Patrick Terheyden; Sebastian Haferkamp; Peter Mohr; Lena Bischof; Elisabeth Livingstone; Lisa Zimmer; Michael Weichenthal; Dirk Schadendorf; Andreas Meiwes; Ulrike Keim; Claus Garbe; Jürgen Christian Becker; Selma Ugurel Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751